Autoantibodies and specific serum proteins in the diagnosis of rheumatological disorders

Annals of Clinical Biochemistry

Volumn 36, Issue 5, 1999, Pages 565-578

  Ismail, Abbas A ^a   Snowden, Neil ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; C REACTIVE PROTEIN; COMPLEMENT; CRYOGLOBULIN; CYTOKINE; IMMUNOGLOBULIN; PLASMA PROTEIN; RHEUMATOID FACTOR;

DISEASE ASSOCIATION; ERYTHROCYTE SEDIMENTATION RATE; HLA TYPING; HUMAN; HUMAN TISSUE; PLASMA VISCOSITY; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RHEUMATOLOGY; SYNOVIAL FLUID;

EID: 0032848192     PISSN: 00045632     EISSN: None     Source Type: Journal    
DOI: 10.1177/000456329903600502     Document Type: Review

References (115)

1. 1 Badley EM, Tennant A. Impact of disablement due to rheumatic disorders in a British population: estimates of severity and prevalence from the Calderdale Rheumatic Disablement Survey. Ann Rheum Dis 1993; 52: 6-13
2. 2 Miles J, Charles P, Riches P. A review of methods available for the identification of organ specific and non-organ specific autoantibodies. Ann Clin Biochem 1998; 35: 19-47
3. 3 Moll J, Haslock I, Macrae IF, Wright V. Associations between ankylosing spondylitis, psoriatic arthritis, Reiter's disease, intestinal arthropathies and Behçet's syndrome. Medicine 1974; 53: 343-64
4. 4 Scott DGI, Watts RA. Classification and epidemiology of systemic vasculitis. Br J Rheumatol 1994, 33: 897-900
5. 5 Ward MM. Evaluative laboratory testing. Assessing tests that assess disease activity. Arthritis Rheum 1995; 38: 1555-63
6. 6 McMorrow ME, Malarkey L. Laboratory and Diagnostic Tests: A Pocket Guide. 1st edn. Philadelphia: WB Saunders Company, 1998
7. 7 Ng T. Erythrocyte sedimentation rate, plasma viscosity and C-reactive protein in clinical practice. Br J Hosp Med 1997; 58: 521-3
8. 8 Young DS, ed. Effects of Drugs on Clinical Laboratory Tests. 3rd edn. Washington DC: AACC, 1990
9. 9 Sox HC, Liang MH. The erythrocyte sedimentation rate. Guidelines for rational use. Ann Intern Med 1986; 140: 515
10. 10 Fex E, Jonsson K, Johnson U, Eberhardt K. Development of radiographic damage during the first 5-6 years of rheumatoid arthritis. A prospective follow-up study of a Swedish cohort. Br J Rheumatol 1996; 35: 1106-15
11. 11 Larsen A. The relation of radiographic changes to serum acute phase proteins and rheumatoid factor in 200 patients with rheumatoid arthritis. Scand J Rheumatol 1988; 17: 123-9
12. 12 Mallya RK, de Beer FC, Berry H, Hamilton ED, Mace BE, Pepys MB. Correlation of clinical parameters of disease activity in rheumatoid arthritis with serum concentration of C-reactive protein and erythrocyte sedimentation rate. J Rheumatol 1982; 9: 224-8
13. 13 Bull BS, Westengard JC, Farr M, Bacon PA, Meyer PJ, Stuart J. Efficacy of tests to monitor rheumatoid arthritis. Lancet 1989; ii: 965
14. 14 Segal R, Caspi D, Tishler M, Wigler I, Yaron M. Short-term effects of low-dose methotrexate on the acute phase reaction in patients with rheumatoid arthritis. J Rheumatol 1989; 16: 914
15. 15 Situnayake RD, McConkey B. Clinical and laboratory effects of prolonged therapy with sulfasalazine, gold, or penicillamine: the effects of disease duration on treatment response. J Rheumatol 1990; 17: 1268
16. 16 Lowe GDO. Should plasma viscosity replace the ESR? Br J Haematol 1994; 86: 6-11
17. 17 Volanakis JE, Xu Y, Macon KJ. Human C-reactive protein and host defense. In: Marchalonis JJ, Reinisch CL, eds. Defense Molecules. New York: Wiley-Liss, Inc. 1990
18. 18 Dixon JS, Bird HA, Sitton NG, Pickup ME, Wright V. C-reactive protein in the serial assessment of disease activity in rheumatoid arthritis. Scand J Rheumatol 1984; 13: 39
19. 19 Nashel DJ, Petrone DL, Ulmer CC, Sliwinski AJ. C-reactive protein: a marker for disease activity in ankylosing spondylitis and Reiter's syndrome. J Rheumatol 1986; 13: 364-7
20. 20 Sanders KM, Hertzman A, Escobar MR, Littman BH. Correlation of immunoglobulin and C-reactive protein levels in ankylosing spondylitis and rheumatoid arthritis. Ann Rheum Dis 1987; 46: 273
21. 21 DaSilva PJA, Elkon KB, Hughes GR, Dyck RF, Pepys MB. C-reactive protein levels in systemic lupus erythematosus: a classification criteria? Arthritis Rheum 1980; 23: 770-1
22. 22 van Leeuwen MA, van Rijswijk MH, van der Heijde DM, Te Meerman GJ, van Riel PL, Houtman PM, et al. The acute phase response in relation to radiographic progression in early rheumatoid arthritis: a prospective study during the first three years of the disease. Br J Rheumatol 1993; 32: 9-13
23. 23 Houssein DA, Jonsson T, Arinbjarnarson S. Clinical significance of IgA rheumatoid factor subclasses in rheumatoid arthritis. J Rheumatol 1997; 24: 2262-3
24. 24 Brennan P, Harrison B, Barrett E, Chakravarty K, Scott D, Silman AJ, et al. A simple algorithm to predict the development of radiological erosions in patients with early rheumatoid arthritis: prospective cohort study. BMJ 1996; 313: 471-6
25. 25 Sherrer YS, Bloch DA, Mitchell DM, Young DY, Fries JF. The development of disability in rheumatoid arthritis. Arthritis Rheum 1986; 26: 494-500
26. 26 Mikkelsen WM, Dodge HJ, Duff IF, Kato H. Estimates of prevalence of rheumatic diseases in the population of Tecumseh, Michigan 1959-1960. J Chron Dis 1967; 20: 351-69
27. 27 Juby AG, Davis P, McElhaney JF, Gravenstein S. Prevalence of selected autoantibodies in different elderly subpopulations. Br J Rheumatol 1994; 33: 1121-4
28. 28 Wolfe F, Cathey MA, Roberts FK. The latex test revisited. Rheumatoid factor testing in 8,287 rheumatic disease patients. Arthritis Rheum 1991; 34: 951-60
29. 29 Smolen JS. Autoantibodies in rheumatoid arthritis. In: van Venrooij WJ, Maini RN, eds. Autoantibody Manual. London: Kluwer Academic Publishers, 1996: 1-18
30. 30 van Zeben D, Hazes JM, Zwinderman AH, Vandenbroucke JP, Breedveld FC. Factors predicting outcome of rheumatoid arthritis: results of a follow-up study. J Rheumatol 1993; 20: 1288-96
31. 31 Gough A, Faint J, Salmon M, Hassell A, Wordsworth P, Pilling D, et al. Genetic typing of patients with inflammatory arthritis at presentation can be used to predict outcome. Arthritis Rheum 1994; 37: 1166-70
32. 32 Feigenbaum SL, Masi AT, Kaplan SB. Prognosis in rheumatoid arthritis. A longitudinal study of newly diagnosed younger adult patients. Am J Med 1979; 66: 377-83
33. 33 Gordon DA, Stein JL, Broder I. The extra-articular features of rheumatoid arthritis. A systematic analysis of 127 cases. Am J Med 1973; 54: 445-52
34. 34 Allen C, Elson CJ, Scott DGI, Bacon PA, Bucknall RC. IgG antiglobulins in rheumatoid arthritis and other arthritides: relationship with clinical features and other parameters. Ann Rheum Dis 1981; 40: 127-31
35. 35 von Essen R, Lehtinen MV, Rasanen JA, Wager O. Reliability of rheumatoid factor tests. Br J Rheumatol 1984; 23: 312-3
36. 36 Aho K, Palosuo T, Puska P, Aromaa A, Salonen JT. When does rheumatoid disease start? Arthritis Rheum 1985; 28: 485-9
37. 37 Jones VE, Jacoby RK, Puttick AH, Cohen BJ. Rheumatoid arthritis: clinical onset, seropositivity, and possible cause. Arthritis Rheum 1986; 29: 814-5
38. 38 Venrooij WJ, Maini RN, eds. Autoantibody Manual. London: Kluwer Academic, 1996
39. 39 IUS/WHO Working Group. Laboratory investigations in clinical immunology: methods, pitfalls and clinical indications. Clin Immunol Immunopath 1988; 49: 478-97
40. 40 Naparstek Y, Plotz PH. The role of autoantibodies in autoimmune disease. Annu Rev Immunol 1993; 11: 79-104
41. 41 Worrall J, Snaith ML, Batchelor R, Isenberg DA. SLE - a rheumatological view. Quart J Med 1990; 275: 319-30
42. 42 Blomgren SE, Condemi JJ, Vaghan JH. Procainamide induced lupus crythematosis. Clinical and laboratory observations. Am J Med 1972; 52: 338
43. 43 Bernstein RM, Steigerwald JC, Tan EM. Association of anti-nuclear and anti-nucleolar antibodies in progressive systemic sclerosis. Clin Exp Immunol 1982; 48: 43
44. 44 Harley JB, Alexander EL, Bias WB, Fox OF, Provost TT, Reichlin M, et al. Anti-Ro/SSA and anti-La/SSB in patients with Sjögren's syndrome. Arthritis Rheum 1986; 29: 196-206
45. 45 Reichlin M, Arnett FC. Multiplicity of antibodies in myositis sera. Arthritis Rheum 1984; 27: 1150
46. 46 Forslid J, Heigl Z, Jonsson J, Scheynius A. The prevalence of antinuclear antibodies in healthy young persons and adults, comparing rat liver tissue sections with HEp-2 cells as antigen substrate. Clin Exp Rheumatol 1994; 12: 137-41
47. 47 Reichlin M, Hanly JB. Antinuclear antibodies: an overview. In: Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus. 5th edn. Baltimore: Williams & Wilkins, 1997: 397-405
48. 48 Alspaugh MA, Talal N, Tan EM. Differentiation and characterisation of autoantibodies and their antigens in Sjögren's syndrome. Arthritis Rheum 1976; 19: 216-22
49. 49 Mattioli M, Reichlin M. Heterogeneity of RNA protein antigens reactive with sera of patients with systemic lupus erythamatosus. Arthritis Rheum 1974; 17: 421-9
50. 50 Provost TT. Anti-Ro (SSA) and anti La (SSB) antibodies in lupus erythematosus and Sjögren's syndrome. Keio J Med 1991; 40: 72-7
51. 51 Sontheimer RD, Madisson PJ, Reichlin M, Jordan RE, Stasthy P, Gilliam JN. Serologic and HLA associations in subacute cutaneous lupus erythematosus, a clinical subset of lupus erythematosus. Ann Intern Med 1982; 97: 664-71
52. 52 Maddison PJ, Provst TT, Reichlin M. Serological findings in patients with 'ANA negative' systemic lupus erythematosus. Medicine 1981; 60: 87-94
53. 53 Maddison PJ, Isenberg DA, Goulding NJ, Leddy J, Skinner AP. Anti La (SSB) identifies a distinctive subgroup of systemic erythematosus. Br J Rheumatol 1988; 27: 27-31
54. 54 Ramsey-Goldman R, Horn D, Deng JS. Anti-SS-A antibodies and fetal outcome in maternal systemic lupus erythematosus. Arthritis Rheum 1986; 29: 1269-73
55. 55 Lane AT, Watson RM. Neonatal lupus erythematosus. Am J Dis Child 1984; 138: 663-6
56. 56 Cassidy JT. SLE, Juvenile dermatomyositis, scleroderma, and vasculitis. In: Kelly WN, Harris ED, Ruddy S, Sledge CB, eds. Textbook of Rheumatology. 4th edn, vol. 2. Philadelphia: WB Saunders, 1993: 1224-47
57. 57 Singsen BH, Akhter JE, Weinstein MM, Sharp GC. Congenital complete heart block and SSA antibodies: obstetric complications. Am J Obstet Gynecol 1985; 512: 655
58. 58 Luhrman R. snRNP proteins. In: Birnsteil ML, ed. Structure and Function of Major and Minor Small Nuclear Ribonucleoprotein Particles. Heidelberg: Springer Verlag, 1988: 71-99
59. 59 Jacobsen S, Halberg P, Ullman S, Van Venrooj WJ, Hoier-Madsen M, Wiik A, et al. Clinical features and serum antinuclear antibodies in 230 Danish patients with systemic sclerosis. Br J Rheumatol 1998; 37: 39-45
60. 60 Matthews MB, Bernstein RM. Myositis autoantibody inhibits histidyl-tRNA synthetase: a model for autoimmunity. Nature 1983; 304: 177-9
61. 61 Targoff IN. Laboratory manifestations of polymyositis/dermatomyositis. Clin Dermatol 1988; 6: 76-92
62. 62 Bernstein RM, Morgan SH, Chapman J. Anti-Jo I antibody: a marker for myositis with interstitial lung disease. BMJ 1984; 289: 151-2
63. 63 Marguerie C, Bunn CC, Beynon HL, Bernstein RM, Hughes JM, So AK, et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med 1990; 77: 1019-38
64. 64 Weestgeest AAA, Boerbooms AMTH, Jongmans M. Anti-perinuclear factor: indicator of more severe disease in seronegative rheumatoid arthritis. J Rheumatol 1987; 14: 893-7
65. 65 Richardson C, Emery P. Laboratory markers of disease activity. J Rheumatol 1996; 23 (suppl 44-46): 23-30
66. 66 Mimori T, Akizuki M, Yamagata H, Inada S, Yoshida S, Homma M. Characterisation of a high molecular weight acidic nuclear protein recognised by auto-antibodies in sera from patients with polymyositis-scleroderma overlap. J Clin Invest 1981; 68: 611-20
67. 67 Okano R, Steen VD, Medsger Jr TA. Serum autoantibodies reactive with RNA polymerase III (RP3), a major autoantigen in systemic sclerosis (SSc) with diffuse cutaneous involvement. Arthritis Rheum 1992; 35 (suppl): 38
68. 68 Targoff IN, Reichlin M. The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum 1985; 28: 796-803
69. 69 Teh LS, Isenberg DA. Anti-ribosomal P protein antibodies in systemic lupus erythematosus: a reappraisal. Arthritis Rheum 1994; 37: 307-15
70. 70 Falkner D, Wilson J, Medsger TA, Morel PA. HLA and clinical associations in systemic sclerosis patients with anti-Th/To antibodies. Arthritis Rheum 1998; 41: 74-80
71. 71 Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7
72. 72 Morris V, Mackworth-Young C. Antiphospholipid antibodies: clinical aspects. In: Venrooij WJ, Maini RN, eds. Autoantibody Manual. London: Kluwer Academic, 1996: 1-14
73. 73 Harris N. Antiphospholipid syndrome. In: Klipel JH, Dieppe PA, eds. Rheumatology. 1st edn, vol. 1. London: Mosby, 1994: 6: 1-6
74. 74 Love PE, Santaro SA. Anti-phospholipid: anti-cardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990; 112: 682-98
75. 75 Balestrieri G, Tincani A, Spatola L, Allegri F, Prati E, Cattaneo R, et al. Anti-Beta(2) glycoprotein 1 antibodies a marker of anti-phospholipid syndrome. Lupus 1995; 4: 122-30
76. 76 Amengual O, Atsumi T, Khamasta MA, Koike T, Hughes GRV. Specificity of ELISA for antibody to B2-glycoprotein 1 in patients with antiphospholipid syndrome. Br J Rheumatol 1996; 35: 1239-43
77. 77 Guerin J, Feighery C, Sim RB, Jackson J. Antibodies to beta(2)-glycoprotein 1 - A specific marker for the antiphospholipid syndrome. Clin Exp Immunol 1997; 109: 304-9
78. 78 Merkel PA, Polisson RP, Chang Y, Skates SJ, Niles JL. Prevalence of anti-neutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease. Ann Intern Med 1997; 126: 867-73
79. 79 Schmitt WH, Csernok E, Gross WL. ANCA and infection. Lancet 1991; 337: 1416-7
80. 80 Niles JL, Bottinger EP, Saurina GR, Kelly KJ, Pan G, Collins AB, et al. The syndrome of lung haemorrhage and nephritis is usually an ANCA associated condition. Arch Intern Med 1996; 156: 440-5
81. 81 Nolle B, Specks U, Ludemann J, Rohrbach MS, DeRenee RA, Gross WL. Anti-cytoplasmic autoantibodies: their immunodiagnostic value in Wegener's Granulomatosis. Ann Intern Med 1989; 111: 28-40
82. 82 Specks U, Homburger HA. Anti-neutrophil cytoplasmic antibodies. Mayo Clin Proc 1994; 69: 1197-8
83. 83 Davenport A, Lock RJ, Wallington T. Clinical significance of the serial measurement of autoantibodies to neutrophil cytoplasm using a standard indirect immunofluorescent test. Am J Nephrol 1995; 15: 201-7
84. 84 Daouk GH, Palsson R, Arnaout MA. Inhibition of proteinase-3 by ANCA and its correlation with disease activity in Wegener's granulomatosis. Kidney Int 1995; 47: 1528-36
85. 85 Kallenberg CGM. Laboratory findings in the vasculitides. Baillière's Clin Rheumatol 1997; 11: 395-421
86. 86 Falk RJ, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotising and cresenteric glomerulonephritis. N Engl J Med 1988; 318: 1651-7
87. 87 Mulder AHL, Brockroelofs J, Horst G, Limburg PC, Nelis GF, Kallenberg CGM. Anti-neutrophil cytoplasmic antibodies (ANCA) in inflammatory bowel disease: Characterisation and clinical correlates. Clin Exp Immunol 1994; 95: 490-7
88. 88 Mulder AHL, Horst G, Van Leuwen MA, Limburg PC, Kallenberg CGM. Antineutrophil cytoplasmic antibodies in rheumatoid arthritis: Characterisation and clinical correlations. Arthritis Rheum 1993; 36: 1054-60
89. 89 Mulder AHL, Horst G, Haagsma EB, Limburg PC, Kleibeuker JH, Kallenberg CGM. Prevalence and characterisation of neutrophil cytoplasmic antibodies in autoimmune liver diseases. Hepatology 1993; 17: 411-7
90. 90 Lipsky PE, Davis LS, Meek K, Wacholtz MC. T cells and B cells. In: Kelley WN, Harris ED, Ruddy S, Sledge CB, eds. Textbook of Rheumatology. 4th edn, vol. 1. Philadelphia: WB Saunders Company, 1993: 108-54
91. 91 Weatherall DJ, Ledingham JGG, Warrell DA, eds. Oxford Textbook of Medicine. 2nd edn, vol. 2. New York: Oxford University Press, 1987
92. 92 Kelly C, Sykes H. Rheumatoid arthritis, malignancy, and paraproteins. Ann Rheum Dis 1990; 49: 657-9
93. 93 Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR, et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978; 89: 888-92
94. 94 Hay EM, Freemont AJ, Kay RA, Bernstein RM, Holt PJ, Pumphrey RS. Selective polyclonal increase of immunoglobulin G1 subclass: a link with Sjögren's syndrome. Ann Rheum Dis 1990; 49: 373-7
95. 95 Hansel TT, Hacney MR, Thompson RA. Primary hypogammaglobulinaemia and arthritis. BMJ 1987; 295: 174-5
96. 96 Snowden N, Dietch DM, Teh LS, Hilton RC, Haency MR. Antibody deficiency associated with gold therapy: natural history and management in 22 patients. Ann Rheum Dis 1996; 55: 616-21
97. 97 Farr M, Tunn EJ, Bacon PA, Smith DH. Hypogammaglobulinaemia and thrombocytopenia associated with sulphasalizine therapy in rheumatoid arthritis. Ann Rheum Dis 1985; 44: 723-4
98. 98 Walport MJ. Complement deficiency and disease. Br J Rheumatol 1993; 32: 269-73
99. 99 Liszewski MK, Kahl LE, Atkinson JP. The functional role of complement genes in systemic lupus erythematosus and Sjögren's syndrome. Curr Opin Rheumatol 1989; 1: 347-52
100. 100 Davies KA. Michael Mason Prize essay 1995. Complement, immune complexes and systemic lupus erythematosus. Br J Rheumatol 1996; 35: 5-23
101. 101 Cicardi M, Agostoni A. Hereditary angioedema. N Engl J Med 1996; 334: 1666-7
102. 102 Morgan BP, Walport MJ. Complement deficiency and disease. Immunol Today 1991; 12: 301-6
103. 103 Schur PH. Complement and SLE. In: Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus. 5th edn. Baltimore: Williams & Wilkins, 1997: 245-61
104. 104 Trendelenburg M, Schifferli JA. Cryoglobulins are not essential. Ann Rheum Dis 1998; 57: 3-5
105. 105 Erhardt CC, Mumford PA, Venables PJW, Maini RN. Factors predicting a poor life prognosis in rheumatoid arthritis: an eight year prospective study. Ann Rheum Dis 1989; 48: 7-13
106. 106 Stastny P. Associations of the B-cell alloantigen Drw4 with rheumatoid arthritis. N Engl J Med 1978; 298: 869-71
107. 107 Wordsworth BP, Lanchbury JSS, Sakkas LI, Welsh KI, Panayi GS, Bell JI. HLA DR4 subtype frequency in rheumatoid arthritis indicates that DRB1 is the major susceptibility locus within the human leukocyte antigen class II region. Proc Natl Acad Sci USA 1989; 86: 10049-53
108. 108 Pile K., Gibson K, Jessop J, Camilleri J, Emberton R, Wordsworth P. HLA DR4 subtyping by single strand polymorphism analysis. Lancet 1993; 342: 300-1
109. 109 Eberhardt K, Fex E, Johnson U, Wollheim FA. HLA-DR and DQ typing in a Swedish cohort of early rheumatoid arthritis limited predictive value for outcome after 2 and 5 years. Ann Rheum Dis 1996; 55: 34-9
110. 110 Bergfeldt L, Edhag O, Rajs J. HLA B27 associated heart disease: Clinicopathologic study of three cases. Am J Med 1984; 77: 961
111. 111 Butler MJ, Russell AS, Percy JS, Lentle BC. A follow up study of 48 patients with Reiter's syndrome. Am J Med 1979; 67: 808
112. 112 Khan MA, Khan MK. HLA-B27 as an aid to the diagnosis of ankylosing spondylitis. Spine 1990; 4: 617
113. 113 Schumacher HR Jr. Synovial fluid analysis and synovial fluid biopsy. In: Kelly WN, Harris ED, Ruddy S, Sledge CB, eds. Textbook of Rheumatology. 4th edn, vol. 1. Philadelphia: WB Saunders, 1993; 562-78
114. 114 Freemont AJ. Microscopic analysis of synovial fluid - the perfect diagnostic test? Ann Rheum Dis 1996; 55: 695-7
115. 115 Freemont AJ, Denton J, Chuck A, Holt PJL, Davies M. Diagnostic value of synovial fluid microscopy: a reassessment and rationalisation. Ann Rheum Dis 1991; 50: 101-7